MGI controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2024
Market reaction to proposed restrictions on U.S. health data transfers
MGI reportedly lost more than one-third of its market capitalization after U.S. congressional legislation was introduced to prohibit or restrict the transfer of American health data to China. The episode reflected continuing geopolitical and data-governance concerns surrounding Chinese genomics companies.
2020
BGI questions fairness of gene-sequencer tender
Issue disclosure
BGI Manufacturing, an unsuccessful bidder, publicly questioned the tender process, alleging that the short timetable and specifications were tailored to Illumina equipment and exclusionary. The report also said the purchase funds might have come from a Tesla donation and noted that the winning equipment was an Illumina product; it described questions about the donation's purpose as allegations.
Source excerpt
参与投标但失利的深圳企业华大智造在其官网公开发文，质疑此次招标程序不正义：在短时间内完成所有招投标流程，是为美国企业illumina的设备量身定做的招标文件，具有明确的排他性。
值得注意的是，采购单位用于此次招标的500万元货款资金，疑似来自特斯拉此前的定向捐赠，而中标设备则是与其存在股东关联的美国企业illumina的产品。这也引发关于捐赠真实目的是利用中国政府机构宣传采购设备的质疑。
2019
U.S. scrutiny over genomic-data processing
U.S. senators raised concerns about the circumstances under which public healthcare programs might finance MGI-related processing of American genomic or exome data. MGI responded that it sells instruments and consumables for customer-operated laboratories and does not own, control, handle, or access customers’ samples or genetic data.